My research focuses on developing an mRNA-based HIV vaccine formulated with lipid nanoparticles (LNPs). The objective is to create a safe and durable LNP-mRNA vaccine by incorporating an adjuvant to enhance and prolong its immunogenicity.
Komla E, Abucayon EG, Godin CS, Sulima A, Jacobson AE, Rice KC, Matyas GR. Safety and Toxicology Profile of TT-6-AmHap Heroin Conjugate Vaccine. Vaccines (Basel). 2025 Jul 26;13(8):792. doi: 10.3390/vaccines13080792. PMID: 40872879; PMCID: PMC12390132.
Komla E, Rochelle C, Carreon A, Torres OB, Matyas GR, Abucayon EG. Red blood cells as probes for determining free QS21 in liposomal adjuvant formulations to support product safety and stability. Anal Methods. 2025 Nov 20;17(45):9162-9170. doi: 10.1039/d5ay00854a. PMID: 41196220.
Komla E, Torres OB, Jalah R, Sulima A, Beck Z, Alving CR, Jacobson AE, Rice KC, Matyas GR. Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice. Vaccines (Basel). 2021 Jun 1;9(6):573. doi: 10.3390/vaccines9060573. PMID: 34205869; PMCID: PMC8229309.
HJF Research Scientist in support of the Laboratory of Antigen and Adjuvant Research (LAAR), U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR)
